ProMIS director granted 16,500 stock options

ProMIS Neurosciences Inc. reported that director Josh Mandel-Brehm received two option grants covering a total of 16,500 options to buy Common Shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. reported that director Josh Mandel-Brehm received two option grants covering a total of 16,500 options to buy Common Shares. One grant covers 11,000 options at an exercise price of $10.77 per share, vesting in full on May 20, 2027, subject to continued Board service. The second grant covers 5,500 options at the same $10.77 exercise price, with 25% vesting immediately on grant and the remaining shares vesting ratably over 36 months, also tied to continued Board service. Both option awards expire on May 20, 2036, and represent compensation-related acquisitions rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 16,500 shares

Grant/Award 2 txns

Insider Mandel-Brehm Josh

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	5,500	$0.00	$0.00
Grant/Award	Option (right to buy)	11,000	$0.00	$0.00

Holdings After Transaction: Option (right to buy) — 16,500 contracts (Direct)

Footnotes (2)

F1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
F2. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

Key Figures

Option grant 1 size: 11,000 options Option grant 2 size: 5,500 options Total underlying shares: 16,500 Common Shares +2 more

5 metrics

Option grant 1 size 11,000 options Option (right to buy) granted to director on May 20, 2026

Option grant 2 size 5,500 options Second option (right to buy) granted on May 20, 2026

Total underlying shares 16,500 Common Shares Shares underlying both option grants

Exercise price $10.77 per share Conversion or exercise price for both option grants

Expiration date May 20, 2036 Expiration for both option awards

Key Terms

Option (right to buy), Grant, award, or other acquisition, vest in full, vesting ratably over thirty-six months

4 terms

Option (right to buy) financial

"security_title: "Option (right to buy)" for both derivative transactions"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest in full financial

"The shares subject to this option shall vest in full on May 20, 2027"

vesting ratably over thirty-six months financial

"remaining shares vesting ratably over thirty-six months, subject to continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ProMIS Neurosciences (PMN) director Josh Mandel-Brehm report on this Form 4?

Josh Mandel-Brehm reported receiving two option awards to acquire a total of 16,500 ProMIS Neurosciences Common Shares. These options are compensation grants, not open-market stock purchases or sales, and give him the right to buy shares at a fixed exercise price.

How many stock options did Josh Mandel-Brehm receive from ProMIS Neurosciences (PMN)?

He received options covering 16,500 underlying Common Shares of ProMIS Neurosciences. One award covers 11,000 shares and a second award covers 5,500 shares, each structured as an option (right to buy) granted as part of his director compensation.

What is the exercise price of the ProMIS Neurosciences (PMN) options granted to Josh Mandel-Brehm?

Both option grants have an exercise price of $10.77 per share. This means Mandel-Brehm can buy ProMIS Neurosciences Common Shares at $10.77 if and when the options vest and are exercised, subject to the vesting and expiration terms.

When do Josh Mandel-Brehm’s ProMIS Neurosciences (PMN) options vest?

The 11,000-share option vests fully on May 20, 2027, if he continues serving on the Board. For the 5,500-share option, 25% vested at grant, with the remaining 75% vesting ratably over 36 months, also conditioned on continued Board service.

When do the ProMIS Neurosciences (PMN) options granted to Josh Mandel-Brehm expire?

Both option awards expire on May 20, 2036, if not exercised earlier. After that expiration date, the options can no longer be used to purchase ProMIS Neurosciences Common Shares, regardless of whether they previously vested.

Does this ProMIS Neurosciences (PMN) Form 4 show any stock sales or purchases by Josh Mandel-Brehm?

The Form 4 shows only option grants classified as acquisitions under transaction code A. There are no reported open-market stock purchases or sales; the filings strictly reflect compensation-related option awards with specified vesting schedules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/22/2026 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mandel-Brehm Josh

(Last)

(First)

(Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO

M4S 3E2

(City)

(State)

(Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option (right to buy)	$10.77	05/20/2026		A		5,500		⁽¹⁾	05/20/2036	Common Shares	5,500	$0	5,500	D
Option (right to buy)	$10.77	05/20/2026		A		11,000		⁽²⁾	05/20/2036	Common Shares	11,000	$0	11,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

2. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

	/s/ Max Milbury, Attorney in Fact for Josh Mandel-Brehm	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR